| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,312 | 0,348 | 18:38 | |
| 0,312 | 0,348 | 18:38 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:36 | FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis | 82 | GlobeNewswire (Europe) | HOUSTON, March 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with... ► Artikel lesen | |
| FIBROBIOLOGICS Aktie jetzt für 0€ handeln | |||||
| Do | FibroBiologics, Inc.: FibroBiologics to Present at the BIO Investment & Growth Summit | 1 | GlobeNewswire (USA) | ||
| Do | H.C. Wainwright cuts FibroBiologics stock price target to $4 | 1 | Investing.com | ||
| Do | H.C. Wainwright senkt Kursziel für FibroBiologics auf 4 US-Dollar | 8 | Investing.com Deutsch | ||
| Di | FibroBiologics, Inc.: FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update | 571 | GlobeNewswire (Europe) | Planning for phase 1/2 clinical trial initiation in Australia utilizing CYWC628 to treat diabetic foot ulcers in the first half of 2026Improved balance sheet through multiple direct offerings; completed... ► Artikel lesen | |
| Di | FibroBiologics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 23.02. | FibroBiologics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.02. | FibroBiologics granted extension by Nasdaq to regain compliance | 14 | Seeking Alpha | ||
| 23.02. | FibroBiologics gets Nasdaq extension to meet listing rules | 15 | Investing.com | ||
| 10.02. | FibroBiologics, Inc.: FibroBiologics' Chairman & CEO Pete O'Heeron Selected to Present at A4LI's H-SPAN Summit at Georgetown University | 4 | GlobeNewswire (USA) | ||
| 06.02. | FibroBiologics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 05.02. | FibroBiologics, Inc.: FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia | 2 | GlobeNewswire (USA) | ||
| 13.01. | After-Hours Biotech Rally: FBLG, NYXH, FBIO, RVTY, OPCH, ATNM, DSGN Climb On Earnings And Momentum | 708 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Several biotech and healthcare names posted notable gains in Monday's after-hours trading session, with moves driven by earnings updates, guidance announcements... ► Artikel lesen | |
| 07.01. | FibroBiologics to begin diabetic foot ulcer clinical trial in Q1 2026 | 5 | Investing.com | ||
| 07.01. | FibroBiologics, Inc.: FibroBiologics CEO Issues Letter to Shareholders | 412 | GlobeNewswire (Europe) | HOUSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development... ► Artikel lesen | |
| 05.01. | FibroBiologics reports positive results for disc degeneration therapy | 2 | Investing.com | ||
| 02.01. | FibroBiologics droht Delisting von der NASDAQ - Unternehmen beantragt Anhörung | 13 | Investing.com Deutsch | ||
| 02.01. | FibroBiologics, Inc. - 8-K, Current Report | 12 | SEC Filings | ||
| 02.01. | FibroBiologics: H.C. Wainwright bestätigt Kaufempfehlung nach IND-Antrag für Psoriasis-Mittel | 10 | Investing.com Deutsch | ||
| 02.01. | FibroBiologics stock maintains Buy rating at H.C. Wainwright on psoriasis IND filing | 2 | Investing.com |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 93,60 | +0,32 % | BioNTech SE: BioNTech veröffentlicht am 10. März 2026 Ergebnisse für das vierte Quartal und das Geschäftsjahr 2025 und informiert über operativen Fortschritt | MAINZ, Deutschland, 24. Februar 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" oder "das Unternehmen") wird am Dienstag, den 10. März 2026, die Ergebnisse für das vierte Quartal und... ► Artikel lesen | |
| MODERNA | 46,325 | +2,16 % | Aufgrund von angeblichen Patentverletzungen zieht BioNTech gegen Moderna vor Gericht | Die Hersteller von Corona-Impfstoffen haben sich schon seit Jahren in den Haaren. Immer wieder gibt es Vorwürfe über Patentverletzungen. So auch in einem aktuellen Fall, bei dem BioNTech gegen den US-Hersteller... ► Artikel lesen | |
| PAION | 0,070 | -22,00 % | PAION AG - Schwächesignale im Fokus | ||
| NOVAVAX | 8,691 | +1,32 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| NANOREPRO | 1,525 | -2,56 % | NanoRepro zündet die nächste Story: Mit PHLAS startet der Sprung ins Premium-SkinTech-Geschäft | NanoRepro geht den nächsten strategischen Schritt - und der hat mit klassischen Selbsttests nur noch am Rand zu tun: Mit dem offiziellen Marktstart des Kaltplasmageräts "PHLAS" und dem Livegang des... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | Morning Market Movers: TechCreate, VivoSim Labs, La Rosa Holdings, Kaixin Holdings See Big Swings | BEIJING (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,500 | -2,60 % | Is Inovio Pharmaceuticals Stock Going to $0? | ||
| INFLARX | 0,780 | +0,13 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| DEFENCE THERAPEUTICS | 0,371 | -1,85 % | Defence Therapeutics Inc.: Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March | Montreal, Quebec--(Newsfile Corp. - March 2, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company advancing... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,322 | -1,19 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Full Year 2025 Financial Results and Provides Business Update | -Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A.... ► Artikel lesen | |
| ABIVAX | 99,60 | -3,11 % | 2 Reasons Abivax Stock Could 10X by 2036 | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,360 | -4,61 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| IBIO | 2,380 | -0,83 % | iBio, Inc. - 8-K, Current Report |